{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T04:09:12Z","timestamp":1686715752287},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00262-023-03411-9","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T11:06:50Z","timestamp":1680174410000},"page":"2541-2548","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer immunity and immunotherapy beyond COVID-19"],"prefix":"10.1007","volume":"72","author":[{"given":"Matteo","family":"Bellone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna","family":"Brevi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Bronte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Dusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Francesco","family":"Ferrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Nistic\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Rosato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Sica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Toietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Paolo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"3411_CR1","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1016\/j.cell.2021.09.020","volume":"184","author":"G Morad","year":"2021","unstructured":"Morad G, Helmink BA, Sharma P, Wargo JA (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184:5309\u20135337. https:\/\/doi.org\/10.1016\/j.cell.2021.09.020","journal-title":"Cell"},{"key":"3411_CR2","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","volume":"76","author":"SM Landow","year":"2017","unstructured":"Landow SM, Gjelsvik A, Weinstock MA (2017) Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992\u20132013. J Am Acad Dermatol 76:258\u2013263. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.018","journal-title":"J Am Acad Dermatol"},{"key":"3411_CR3","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/jid.2014.452","volume":"135","author":"DC Whiteman","year":"2015","unstructured":"Whiteman DC, Baade PD, Olsen CM (2015) More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland. Austr J Invest Dermatol 135:1190\u20131193. https:\/\/doi.org\/10.1038\/jid.2014.452","journal-title":"Austr J Invest Dermatol"},{"key":"3411_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2020.08.029","volume":"140","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Bellomo D, Arias-Mejias SM et al (2020) Identification of stage I\/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. Eur J Cancer 140:11\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2020.08.029","journal-title":"Eur J Cancer"},{"key":"3411_CR5","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1182\/blood-2013-04-493361","volume":"122","author":"M Casucci","year":"2013","unstructured":"Casucci M, Nicolis di Robilant B, Falcone L et al (2013) CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood 122:3461\u20133472. https:\/\/doi.org\/10.1182\/blood-2013-04-493361","journal-title":"Blood"},{"key":"3411_CR6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41467-019-08871-1","volume":"10","author":"M Noviello","year":"2019","unstructured":"Noviello M, Manfredi F, Ruggiero E et al (2019) Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun 10:1065. https:\/\/doi.org\/10.1038\/s41467-019-08871-1","journal-title":"Nat Commun"},{"key":"3411_CR7","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"397","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam F, Larkin J, Tabernero J, Bonini C (2021) Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet 397:1010\u20131022. https:\/\/doi.org\/10.1016\/S0140-6736(20)32598-8","journal-title":"Lancet"},{"key":"3411_CR8","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","volume":"398","author":"E Felip","year":"2021","unstructured":"Felip E, Altorki N, Zhou C et al (2021) Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398:1344\u20131357. https:\/\/doi.org\/10.1016\/S0140-6736(21)02098-5","journal-title":"Lancet"},{"key":"3411_CR9","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","volume":"397","author":"A Sezer","year":"2021","unstructured":"Sezer A, Kilickap S, Gumus M et al (2021) Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet 397:592\u2013604. https:\/\/doi.org\/10.1016\/S0140-6736(21)00228-2","journal-title":"Lancet"},{"key":"3411_CR10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2021-0380","author":"C Caruso","year":"2021","unstructured":"Caruso C (2021) Three-drug regimen bests chemo in NSCLC. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2021-0380","journal-title":"Cancer Discov"},{"key":"3411_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:44\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(19)30689-8","journal-title":"Lancet Oncol"},{"key":"3411_CR12","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"issue":"135\u2013146","key":"3411_CR13","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.cell.2017.11.025","volume":"172","author":"S Bekkering","year":"2018","unstructured":"Bekkering S, Arts RJW, Novakovic B et al (2018) Metabolic induction of trained immunity through the mevalonate pathway. Cell 172(135\u2013146):e9. https:\/\/doi.org\/10.1016\/j.cell.2017.11.025","journal-title":"Cell"},{"key":"3411_CR14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.chom.2020.05.014","volume":"28","author":"B Cirovic","year":"2020","unstructured":"Cirovic B, de Bree LCJ, Groh L et al (2020) BCG Vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment. Cell Host Microbe 28:322\u201334. https:\/\/doi.org\/10.1016\/j.chom.2020.05.014","journal-title":"Cell Host Microbe"},{"key":"3411_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2020.08.051","volume":"183","author":"EJ Giamarellos-Bourboulis","year":"2020","unstructured":"Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S et al (2020) Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell. 183:315\u2013323. https:\/\/doi.org\/10.1016\/j.cell.2020.08.051","journal-title":"Cell."},{"issue":"147","key":"3411_CR16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.cell.2017.11.034","volume":"172","author":"I Mitroulis","year":"2018","unstructured":"Mitroulis I, Ruppova K, Wang B et al (2018) Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell 172(147):161. https:\/\/doi.org\/10.1016\/j.cell.2017.11.034","journal-title":"Cell"},{"key":"3411_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.cell.2020.09.058","volume":"183","author":"L Kalafati","year":"2020","unstructured":"Kalafati L, Kourtzelis I, Schulte-Schrepping J et al (2020) Innate immune training of granulopoiesis promotes anti-tumor activity. Cell 183:771\u2013785. https:\/\/doi.org\/10.1016\/j.cell.2020.09.058","journal-title":"Cell"},{"key":"3411_CR18","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","volume":"39","author":"AM Leader","year":"2021","unstructured":"Leader AM, Grout JA, Maier BB et al (2021) Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 39:1594\u2013609. https:\/\/doi.org\/10.1016\/j.ccell.2021.10.009","journal-title":"Cancer Cell"},{"key":"3411_CR19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","volume":"580","author":"B Maier","year":"2020","unstructured":"Maier B, Leader AM, Chen ST et al (2020) A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580:257\u2013262. https:\/\/doi.org\/10.1038\/s41586-020-2134-y","journal-title":"Nature"},{"key":"3411_CR20","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-021-24343-x","volume":"12","author":"S Valpione","year":"2021","unstructured":"Valpione S, Mundra PA, Galvani E et al (2021) The T cell receptor repertoire of tumor infiltrating T cells is predictive and prognostic for cancer survival. Nat Commun 12:4098. https:\/\/doi.org\/10.1038\/s41467-021-24343-x","journal-title":"Nat Commun"},{"key":"3411_CR21","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/2326-6066.CIR-20-0645","volume":"9","author":"G Morello","year":"2021","unstructured":"Morello G, Cancila V, La Rosa M et al (2021) T cells expressing receptor recombination\/revision machinery are detected in the tumor microenvironment and expanded in genomically over-unstable models. Cancer Immunol Res 9:825\u2013837. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0645","journal-title":"Cancer Immunol Res"},{"key":"3411_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","volume":"6","author":"G Kichenadasse","year":"2020","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, Rowland A, Hopkins AM, Sorich MJ (2020) Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer. JAMA Oncol 6:512\u2013518. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5241","journal-title":"JAMA Oncol"},{"key":"3411_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2015.07.006","volume":"28","author":"L Strauss","year":"2015","unstructured":"Strauss L, Sangaletti S, Consonni FM et al (2015) RORC1 regulates tumor-promoting \u201cemergency\u201d granulo-monocytopoiesis. Cancer Cell 28:253\u2013269. https:\/\/doi.org\/10.1016\/j.ccell.2015.07.006","journal-title":"Cancer Cell"},{"key":"3411_CR24","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1158\/0008-5472.CAN-18-1544","volume":"79","author":"C Travelli","year":"2019","unstructured":"Travelli C, Consonni FM, Sangaletti S et al (2019) Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells. Cancer Res 79:1938\u20131951. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1544","journal-title":"Cancer Res"},{"key":"3411_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41590-021-00921-5","volume":"22","author":"FM Consonni","year":"2021","unstructured":"Consonni FM, Bleve A, Totaro MG et al (2021) Heme catabolism by tumor-associated macrophages controls metastasis formation. Nat Immunol 22:595\u2013606. https:\/\/doi.org\/10.1038\/s41590-021-00921-5","journal-title":"Nat Immunol"},{"key":"3411_CR26","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41586-021-03326-4","volume":"591","author":"R Zappasodi","year":"2021","unstructured":"Zappasodi R, Serganova I, Cohen IJ et al (2021) CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. Nature 591:652\u2013658. https:\/\/doi.org\/10.1038\/s41586-021-03326-4","journal-title":"Nature"},{"key":"3411_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.138581","author":"A Ugolini","year":"2020","unstructured":"Ugolini A, Tyurin VA, Tyurina YY, Tcyganov EN, Donthireddy L, Kagan VE, Gabrilovich DI, Veglia F (2020) Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.138581","journal-title":"JCI Insight"},{"key":"3411_CR28","doi-asserted-by":"publisher","DOI":"10.1172\/JCI145971","author":"EN Tcyganov","year":"2021","unstructured":"Tcyganov EN, Hanabuchi S, Hashimoto A et al (2021) Distinct mechanisms govern populations of myeloid-derived suppressor cells in chronic viral infection and cancer. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI145971","journal-title":"J Clin Invest"},{"key":"3411_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abb5817","author":"M Perego","year":"2020","unstructured":"Perego M, Tyurin VA, Tyurina YY et al (2020) Reactivation of dormant tumor cells by modified lipids derived from stress-activated neutrophils. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abb5817","journal-title":"Sci Transl Med"},{"key":"3411_CR30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20191920","author":"T Manzo","year":"2020","unstructured":"Manzo T, Prentice BM, Anderson KG et al (2020) Accumulation of long-chain fatty acids in the tumor microenvironment drives dysfunction in intrapancreatic CD8+ T cells. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20191920","journal-title":"J Exp Med"},{"key":"3411_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.copbio.2020.10.011","volume":"68","author":"NC Flerin","year":"2021","unstructured":"Flerin NC, Cappellesso F, Pretto S, Mazzone M (2021) Metabolic traits ruling the specificity of the immune response in different cancer types. Curr Opin Biotechnol 68:124\u2013143. https:\/\/doi.org\/10.1016\/j.copbio.2020.10.011","journal-title":"Curr Opin Biotechnol"},{"key":"3411_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.it.2021.03.006","volume":"42","author":"HH Van Acker","year":"2021","unstructured":"Van Acker HH, Ma S, Scolaro T, Kaech SM, Mazzone M (2021) How metabolism bridles cytotoxic CD8(+) T cells through epigenetic modifications. Trends Immunol 42:401\u2013417. https:\/\/doi.org\/10.1016\/j.it.2021.03.006","journal-title":"Trends Immunol"},{"key":"3411_CR33","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez CX, Muller S, Keerthivasan S et al (2020) Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov 10:232\u2013253. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0644","journal-title":"Cancer Discov"},{"key":"3411_CR34","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1158\/0008-5472.CAN-18-0327","volume":"78","author":"JW Purcell","year":"2018","unstructured":"Purcell JW, Tanlimco SG, Hickson J et al (2018) LRRC15 is a novel mesenchymal protein and stromal target for antibody-drug conjugates. Cancer Res 78:4059\u20134072. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-0327","journal-title":"Cancer Res"},{"key":"3411_CR35","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41422-019-0195-y","volume":"29","author":"J Peng","year":"2019","unstructured":"Peng J, Sun BF, Chen CY et al (2019) Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Cell Res 29:725\u2013738. https:\/\/doi.org\/10.1038\/s41422-019-0195-y","journal-title":"Cell Res"},{"key":"3411_CR36","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1126\/science.abc3421","volume":"369","author":"LF Mager","year":"2020","unstructured":"Mager LF, Burkhard R, Pett N et al (2020) Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science 369:1481\u20131489. https:\/\/doi.org\/10.1126\/science.abc3421","journal-title":"Science"},{"key":"3411_CR37","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","volume":"9","author":"A Calcinotto","year":"2018","unstructured":"Calcinotto A, Brevi A, Chesi M et al (2018) Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression. Nat Commun 9:4832. https:\/\/doi.org\/10.1038\/s41467-018-07305-8","journal-title":"Nat Commun"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03411-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-023-03411-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-023-03411-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T12:09:32Z","timestamp":1686658172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-023-03411-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["3411"],"URL":"https:\/\/doi.org\/10.1007\/s00262-023-03411-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"PFF has received honorarium for advisory board participation from: Bristol Meyers Squibb, Novartis, MSD, Pierre Fabre and Roche. VB reports relationship with IoBiotech Aps and Codiak BioScience (personal fees), outside the submitted work. All other authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}